Skip to ContentSkip to Navigation
founded in 1614  -  top 100 university
About us Practical matters How to find us prof. dr. T. van Meerten
University Medical Center Groningen

prof. dr. T. van Meerten

No picture available
E-mail:
t.van.meerten umcg.nl

Publications

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network

A Novel Hypothermic Preservation Formulation Containing SUL-138 Enables Long-Term Hypothermic Storage of Clinical-Grade CAR-T Cells

Author Correction: Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study.

A versatile and GMP-compliant bead-based IFN-γ potency assay for standardized quality control and release testing of CAR-T cell drug products

Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3

Impact of Rituximab Maintenance on Survival in Patients with Mantle Cell Lymphoma; a Population-based Cohort Study

Multi-omic profiling and preclinical efficacy of fratricide-driven, unedited CD7 CAR-T cells in T-cell leukemia

Outcomes of patients over 70 years treated with brexu-cel for R/R mantle cell lymphoma: a study from the CTIWP of EBMT

Separation of simultaneously acquired [89Zr]atezolizumab and [18F]FDG PET scans

1764 Decrease of metabolic active tumour volume of target- and unintentionally irradiated lesions after bridging radiotherapy prior to CAR T-cell therapy

Press/media

Je eigen bloedcellen als medicijn tegen een auto-immuunziekte of bloedkanker

Dr van Meerten on the Optimal Use of Brexu-Cel in BTK Inhibitor–Naive MCL

Dr van Meerten on the Role of Brexu-Cel in High-Risk MCL

Prof. Tom van Meerten (UMCG) over beta-hydroxybutyraat en CAR T-cel fitness

Subsidie voor onderzoek CAR-T-cellen voor mensen met multipel myeloom

Onderzoek naar effect CAR T-cellen bij terugkerende beenmergkanker krijgt subsidie

Gronings UMC gaat met overheidssubsidie zelf een prijzig buitenlands kankermedicijn maken

16,5 miljoen subsidie voor onderzoek CAR T-cellen bij beenmergkanker

Wat is de potentie van CAR-Tceltherapie bij terugkerende beenmergkanker?

UMCG krijgt miljoenen voor nieuwe behandeling van beenmergkanker: 'Je wint tijd'

Sustainable Development Goals

SDG 3 - Good Health and Well-beingSDG 7 - Affordable and Clean EnergySDG 9 - Industry, Innovation, and Infrastructure

More information about the Sustainable Development Goals.